Multi-Peptide Protocol

Cognitive Enhancement: Semax + Selank

Semax and Selank are research chemicals in most jurisdictions. While approved in Russia as prescription medications, they are not FDA-approved. This protocol is for educational purposes only.
Contraindications — Do Not Use If:

Severe hypertension. Semax may elevate blood pressure through its stimulatory and catecholaminergic effects. Uncontrolled or severe hypertension is a contraindication.[1]

Active mania or psychosis. Semax enhances dopaminergic and serotonergic transmission, which may exacerbate manic episodes or psychotic symptoms.[2]

Seizure disorders. Both peptides modulate central neurotransmitter systems and may lower seizure threshold in susceptible individuals.[3]

Pregnancy or breastfeeding. No reproductive toxicology data exist for either compound in humans.

Hypersensitivity to ACTH-derived peptides. Semax is a synthetic analog of the ACTH(4-10) fragment. Patients with known allergy to ACTH or corticotropin should not use Semax.

Limited Western Clinical Data

The majority of clinical research on Semax and Selank has been conducted in Russia and published in Russian-language journals. While some studies have been translated or replicated in Western settings, the overall evidence base does not meet the standards typically required for FDA approval. Practitioners should interpret the available data accordingly.

Rationale for Combination

Semax and Selank are complementary neuropeptides that target different but synergistic aspects of cognitive function. Semax provides cognitive stimulation and neuroprotection, while Selank offers anxiolytic support and emotional stability — together addressing both the drive and composure required for optimal cognitive performance.

Semax: Cognitive Drive & Neuroprotection

Semax is a synthetic analog of the ACTH(4-10) fragment with a Pro-Gly-Pro C-terminal extension that confers metabolic stability. Its primary mechanisms relevant to cognitive enhancement include:

  • BDNF upregulation: Semax significantly enhances brain-derived neurotrophic factor (BDNF) expression in the hippocampus and cortex, promoting synaptic plasticity and long-term potentiation.[1]
  • Dopamine and serotonin modulation: Semax increases dopaminergic and serotonergic turnover in the brain, enhancing attention, motivation, and working memory.[2]
  • Neuroprotection: In animal models of cerebral ischemia, Semax demonstrated significant neuroprotective effects, reducing infarct volume and preserving neuronal function.[4]
  • Neurotrophin cascade activation: Beyond BDNF, Semax modulates NGF and NT-3 expression, supporting a broad neurotrophic environment.[5]

Selank: Anxiolytic & Emotional Balance

Selank is a synthetic analog of the naturally occurring immunomodulatory peptide tuftsin (threonyl-lysyl-prolyl-arginine), with a Gly-Pro extension. Its mechanisms include:

  • GABAergic enhancement: Selank increases GABA transmission in the brain, producing anxiolytic effects comparable to benzodiazepines but without sedation or dependence.[6]
  • Enkephalin stabilization: Selank inhibits enkephalin-degrading enzymes, prolonging the activity of endogenous opioid peptides involved in stress resilience and mood regulation.[7]
  • IL-6 modulation: Selank modulates interleukin-6 expression, providing an immunomodulatory component to its anxiolytic profile.[8]
  • Cognitive stabilization under stress: By reducing anxiety without cognitive impairment, Selank allows sustained cognitive performance in high-stress environments.[3]

Complementary Pairing: Semax is stimulating and pro-cognitive, while Selank is calming and anxiolytic. When combined, they address the common problem of cognitive stimulants producing anxiety — Selank counterbalances the activating effects of Semax, enabling focused performance without agitation.

Per-Component Dosing

The following dosing information reflects commonly reported protocols from Russian clinical literature and practitioner experience. Individual responses vary, and dosing should be guided by a supervising clinician.

Parameter Semax Selank
Typical dose 200 – 600 mcg 250 – 500 mcg
Frequency 1–2x daily, morning preferred 1–3x daily, can be used throughout day
Route Intranasal (primary) Intranasal (primary)
Onset Minutes to hours 30 – 60 minutes
Alternative route Subcutaneous Subcutaneous
Storage Refrigerated (2–8 °C) Refrigerated (2–8 °C)
Administration: Intranasal Technique

Intranasal delivery is the primary route for both peptides because it bypasses the blood-brain barrier efficiently via the olfactory and trigeminal nerve pathways. For best results: clear nasal passages before administration, tilt head slightly forward, insert the spray nozzle just inside the nostril, aim toward the outer wall (not the septum), and sniff gently — do not inhale forcefully. Alternate nostrils between doses. Subcutaneous injection is a viable alternative route, though intranasal is preferred for CNS-targeted effects.

Cycle Structure

Both Semax and Selank can be used in continuous cycles, but periodic breaks are recommended to prevent tolerance and maintain efficacy:

Standard Cycle: 2–4 Weeks On / 1–2 Weeks Off

  • Semax: 200–600 mcg intranasal, 1–2x daily for 2–4 weeks. Start at the lower dose and increase after 3–5 days if tolerated and desired effect is insufficient.
  • Selank: 250–500 mcg intranasal, 1–3x daily for 2–4 weeks. Can be used concurrently with Semax or independently as needed for anxiety.
  • Follow each cycle with 1–2 weeks off both peptides to reset receptor sensitivity.

Alternative: 5 Days On / 2 Days Off

  • Some users cycle both peptides on weekdays and take weekends off to maintain sensitivity.
  • This pattern may be sustained for longer periods (6–8 weeks) before a full 2-week break.

Expected Timeline

Unlike many peptide protocols that require weeks to produce noticeable effects, Semax and Selank often produce perceptible changes rapidly:

  • Semax: Improved focus, verbal fluency, and mental clarity often noticeable within hours of the first dose. Full cognitive enhancement effects typically develop over 3–5 days of consistent use.[1]
  • Selank: Anxiety reduction typically begins within 30–60 minutes of intranasal administration. Sustained anxiolytic effects and mood stabilization develop over 5–7 days of regular use.[6]
  • Combined effects: Users commonly report an enhanced state of "calm focus" emerging within the first 2–3 days of combined use, peaking during the second week.

Monitoring Guidance

Given the limited formal safety data in Western medical literature, monitoring should be thorough and systematic:

What to Track

  • Blood pressure: Semax may elevate blood pressure. Monitor at baseline and weekly, especially during the first two weeks. Discontinue if sustained systolic elevation >15 mmHg from baseline.
  • Mood and anxiety tracking: Use a validated subjective scale (e.g., GAD-7 for anxiety, PHQ-9 for mood) at baseline, weekly, and at protocol completion. Daily journaling of subjective cognitive state is recommended.
  • Cognitive performance: Optional neuropsychological testing (e.g., N-back task, Stroop test, Trail Making Test) at baseline and at 2-week intervals can provide objective data on cognitive changes.
  • Liver function: ALT, AST, and bilirubin at baseline and at protocol completion as a standard safety measure.
  • Thyroid function: TSH and free T4 at baseline and after each cycle. ACTH-derived peptides may theoretically influence the hypothalamic-pituitary axis.

When to Stop

  • Sustained blood pressure elevation above acceptable thresholds
  • Onset or worsening of anxiety, agitation, or manic symptoms
  • Persistent headaches or nasal irritation that does not resolve with dose reduction
  • Any signs of allergic reaction (nasal swelling, urticaria, breathing difficulty)
  • New seizure activity or worsening of pre-existing neurological conditions
  • Significant hair shedding (rare, reported at higher Semax doses)

Side Effects

Semax

  • Nasal irritation: Mild burning or dryness at the administration site, typically transient and resolving with continued use
  • Headache: Rare; usually mild and self-limiting, more common at higher doses
  • Hair loss: Reported anecdotally at high doses (>600 mcg/day); mechanism unclear but may relate to BDNF modulation of hair follicle cycling[9]
  • Mild blood pressure elevation: Transient increases in systolic blood pressure have been reported, particularly in patients with pre-existing hypertension[1]

Selank

  • Nasal irritation: Similar to Semax; mild burning or dryness at the administration site
  • Fatigue: Reported at higher doses, likely related to enhanced GABAergic transmission[6]
  • Vivid dreams: Rarely reported; may relate to effects on enkephalin metabolism and sleep architecture

Drug Interactions

No formal drug interaction studies have been conducted for the Semax + Selank combination. The following are theoretical considerations based on known mechanisms:

  • SSRIs/SNRIs: Semax enhances serotonergic transmission. Concurrent use with serotonin reuptake inhibitors may increase the risk of serotonin syndrome. Monitor for agitation, hyperthermia, clonus, and hyperreflexia.[2]
  • Stimulants (amphetamines, methylphenidate): Additive dopaminergic and noradrenergic effects with Semax. May increase cardiovascular risk and overstimulation. Use with caution and enhanced monitoring.
  • Benzodiazepines: Additive GABAergic effects with Selank. While Selank does not appear to potentiate benzodiazepine sedation to the same degree as benzodiazepine-benzodiazepine combinations, caution is warranted.[6]
  • MAOIs: Contraindicated with Semax. MAO inhibitors combined with Semax's enhancement of monoamine turnover could precipitate hypertensive crisis or serotonin syndrome.
  • Anticoagulants: Selank's parent peptide tuftsin has immunomodulatory properties. No direct anticoagulant interaction is expected, but monitor if used concurrently with blood thinners.

Related Videos

Neuroplasticity, focus, and cognitive enhancement science — Huberman Lab

Neuropeptides including Semax and Selank for cognitive function — Huberman Lab

References

  1. Aseeva EN, Miasoedov NF, Lyapina LA, et al. The effects of Semax on the expression of BDNF and its receptor TrkB in the rat hippocampus. Doklady Biological Sciences. 2007;414:236-238. doi:10.1134/S0012496607030167. PMID: 17695307.
  2. Dolotov OV, Karpenko EA, Inozemtseva LS, et al. Semax, an analog of ACTH(4-10) with cognitive effects, regulates BDNF and trkB expression in the rat hippocampus. Brain Research. 2006;1117(1):54-60. doi:10.1016/j.brainres.2006.07.108. PMID: 16996040.
  3. Zozulya AA, Sizov SV, Semenova TP, et al. The inhibitory effect of Selank on enkephalin-degrading enzymes as a possible mechanism of its anxiolytic activity. Bulletin of Experimental Biology and Medicine. 2001;131(4):315-317. doi:10.1023/A:1017979514274. PMID: 11550013.
  4. Dolotov OV, Mezhlumyan AG, Goldina YI, et al. Neuroprotective effect of Semax in conditions of global cerebral ischemia in Mongolian gerbils. Bulletin of Experimental Biology and Medicine. 2003;135(Suppl 1):56-58. PMID: 12949686.
  5. Agapova TYu, Agniullin YV, Silachev DN, et al. Effect of Semax on the expression of neurotrophins and their receptors in the rat brain during incomplete global ischemia. Molekulyarnaya Biologiya. 2008;42(5):843-848.
  6. Semenova TP, Kozlovskaya MM, Zuikov AV, et al. Selank and its metabolites maintain the effects of diazepam in the GABA-benzodiazepine receptor complex. Bulletin of Experimental Biology and Medicine. 2006;141(5):593-596. doi:10.1007/s10517-006-0227-7. PMID: 17152966.
  7. Kozlovskii II, Danchev ND, Zhilenko MI. The optimizing action of the synthetic peptide Selank on a conditioned active avoidance reflex in rats. Neuroscience and Behavioral Physiology. 2003;33(7):639-643. doi:10.1023/A:1024444012703. PMID: 14552528.
  8. Uchakina ON, Uchakin PN, Miasoedov NF, et al. Immunomodulatory effects of Selank in patients with anxiety-asthenic disorders. Zhurnal Nevrologii i Psikhiatrii imeni S.S. Korsakova. 2008;108(5):71-75. PMID: 18577961.
  9. Miasoedov NF, Skvortsova VI, Nasonov EL, et al. Investigation of mechanisms of neuroprotective effect of Semax in acute period of ischemic stroke. Zhurnal Nevrologii i Psikhiatrii imeni S.S. Korsakova. 1999;99(5):15-19. PMID: 10441282.
  10. Kozlovskaya MM, Kozlovskii II, Valdman EA, Seredenin SB. Selank and short peptides of the tuftsin family in the regulation of adaptive behavior in stress. Neuroscience and Behavioral Physiology. 2003;33(9):853-860. doi:10.1023/A:1025988519919. PMID: 14969420.
  11. Levitskaya NG, Sebentsova EA, Andreeva LA, et al. The neuroprotective effects of Semax in conditions of modeled incomplete ischemia of the brain. Doklady Biological Sciences. 2004;394:15-18. PMID: 15088443.
  12. Medvedev VE, Tereshin AE, Korotkova EV. Efficacy of Selank in treatment of anxiety disorders. Zhurnal Nevrologii i Psikhiatrii imeni S.S. Korsakova. 2014;114(6):73-78. PMID: 25176270.